Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) has been added to the Russell 2000 and Russell 3000 indexes, effective June 29, 2026, as part of the 2026 Russell reconstitution.
The company plans to start a U.S. Phase 3 trial of denifanstat for moderate to severe acne in patients 12+ in the second half of 2026 and reports having capital to fund its programs, including this trial, through 2028.
Positive
- Added to Russell 2000 and Russell 3000 indexes effective June 29, 2026
- Plans to initiate U.S. Phase 3 denifanstat acne trial in 2H 2026
- Capital in place to fund programs, including Phase 3 data readout, through 2028
Negative
- None.
News Market Reaction – SGMT
In the Jun 29 session, SGMT gained 10.34%, reflecting a significant positive market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | Investor conference | Positive | -0.6% | Upcoming investor meetings and inducement stock option grant disclosure under Nasdaq rules. |
| May 27 | Clinical data update | Positive | +0.0% | Phase 1 denifanstat/resmetirom combo data and supportive preclinical MASH results at EASL. |
| May 13 | Investor conference | Positive | -0.7% | Participation and webcasted fireside chat at H.C. Wainwright BioConnect conference. |
| May 12 | Earnings & update | Positive | -0.5% | Q1 2026 results, $175M financing and acne program runway through 2028. |
| May 11 | Scientific presentation | Positive | -0.3% | New FASN inhibitor mechanism-of-action data supporting a planned U.S. acne Phase 3 trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate and clinical updates have typically been followed by flat-to-negative price reactions.
Key Terms
russell 2000® index financial
russell 3000® index financial
ftse russell financial
phase 3 clinical trial medical
acne vulgaris medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution.
The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for half a year beginning in 2026, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“We believe inclusion in the Russell indexes reflects the meaningful progress Sagimet has made over the last year, as we plan to initiate our U.S. Phase 3 clinical trial of denifanstat in moderate to severe acne, including adolescent patients aged 12 years and older, in the second half of this year. If approved, denifanstat would be the first innovative oral treatment for acne vulgaris in patients aged 12 years and older in more than forty years,” said David Happel, Chief Executive Officer of Sagimet. “With the capital in place to fund our programs through 2028, including data readout of our planned denifanstat Phase 3 clinical trial in acne, we look forward to the broader visibility that inclusion in the Russell indexes brings.”
For further information on Russell index methodology and reconstitution, please visit FTSE Russell at www.lseg.com/en/ftse-russell.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related timelines and anticipated development milestones, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
